AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10220792 — intervention group
Group type: COMPARATOR
Intervention: Hp-induced erosions
Number of subjects: 122
Study 10220792 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological diagnosis of NSAID/ASA-induced erosions
Number of subjects: 122
Study 7604928 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (policy workbook and consultation via meetings and telephone calls)
Number of subjects: 39
Study 7604928 — intervention group
Group type: COMPARATOR
Intervention: Late intervention (no assistance or encouragement regarding tobacco use policies)
Number of subjects: 39
Study 2223358 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (12 patients)
Number of subjects: 23
Study 2223358 — intervention group
Group type: COMPARATOR
Intervention: Halothane (11 patients)
Number of subjects: 23
Study 2223358 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged administration of 1% isoflurane (5 patients)
Number of subjects: 23
Study 27204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (4 mg)
Number of subjects: 6
Study 27204 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (1 mg)
Number of subjects: 6
Study 27204 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (10 mg)
Number of subjects: 6
Study 27204 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 6
Study 27204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31176540 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-13 (Prevenar-13)
Number of subjects: 0
Study 28295923 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 48 weeks
Number of subjects: 50
Study 26418222 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HITR)
Number of subjects: 34
Study 26418222 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Continuous Training (HCTR)
Number of subjects: 34
Study 26418222 — intervention group
Group type: COMPARATOR
Intervention: Sedentary Control (SED)
Number of subjects: 34
Study 22922554 — intervention group
Group type: EXPERIMENTAL
Intervention: Education/Exercise combined (EXE)
Number of subjects: 23
Study 22922554 — intervention group
Group type: COMPARATOR
Intervention: Education only (EDU)
Number of subjects: 23
Study 21159081 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based management of malaria + Seasonal intermittent preventive treatment (IPTc) with AS+AQ
Number of subjects: 30
Study 21159081 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based management of malaria + Seasonal intermittent preventive treatment (IPTc) with AS+AQ (only children who received all three courses of IPTc)
Number of subjects: 30
Study 21159081 — intervention group
Group type: COMPARATOR
Intervention: Home-based management of malaria (HMM) alone
Number of subjects: 30
Study 19809023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF) 100 mg/d
Number of subjects: 472
Study 19809023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF) 100 mg/d plus Lactobacillus rhamnosus GG (LGG) 6 x 10(9) colony-forming units/d
Number of subjects: 472
Study 19809023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 18174120 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal plus optional Internet response arm
Number of subjects: 4213
Study 18174120 — intervention group
Group type: COMPARATOR
Intervention: Usual postal survey arm
Number of subjects: 4213
Study 18174120 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional Internet response arm
Number of subjects: 4213
Study 18174120 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference
Number of subjects: 4213
Study 15184627 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA and tirofiban (n = 13)
Number of subjects: 47
Study 15184627 — intervention group
Group type: COMPARATOR
Intervention: rtPA only (n = 16)
Number of subjects: 47
Study 15184627 — intervention group
Group type: COMPARATOR
Intervention: Nontreated patients (n = 18)
Number of subjects: 47
Study 11599908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node dissection
Number of subjects: 0
Study 11599908 — intervention group
Group type: COMPARATOR
Intervention: Routine axillary node dissection
Number of subjects: 0
Study 9503114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium prophylaxis
Number of subjects: 55
Study 9503114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 55
Study 9503114 — intervention group
Group type: EXPERIMENTAL
Intervention: Case patients (with SSI)
Number of subjects: 55
Study 9503114 — intervention group
Group type: COMPARATOR
Intervention: Control patients (without SSI)
Number of subjects: 55
Study 7845753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (65 mg/kg/day once daily, Group A, n = 25)
Number of subjects: 50
Study 7845753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefixime (10 mg/kg/day divided every 12 hours, Group B, n = 25)
Number of subjects: 50
Study 7845753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (Group A)
Number of subjects: 50
Study 7845753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefixime (Group B)
Number of subjects: 50
Study 7845753 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 3293973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 236
Study 3293973 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin plus Penicillin (N + P)
Number of subjects: 236
Study 30813584 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ounces of nuts
Number of subjects: 18
Study 30813584 — intervention group
Group type: COMPARATOR
Intervention: 2 ounces of dairy
Number of subjects: 18
Study 28580864 — intervention group
Group type: EXPERIMENTAL
Intervention: School policy changes in 16 schools, marketing campaign, increased social support and role modeling
Number of subjects: 904
Study 28580864 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed-intervention condition)
Number of subjects: 904
Study 26257323 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop therapy with standard prandial insulin boluses
Number of subjects: 8
Study 26257323 — intervention group
Group type: COMPARATOR
Intervention: Closed-loop therapy with prandial boluses reduced by 25%
Number of subjects: 8
Study 23914920 — intervention group
Group type: EXPERIMENTAL
Intervention: Innocent suspects during interrogation
Number of subjects: 132
Study 23914920 — intervention group
Group type: EXPERIMENTAL
Intervention: Innocent suspects who refused to confess
Number of subjects: 132
Study 23914920 — intervention group
Group type: COMPARATOR
Intervention: Guilty suspects during interrogation
Number of subjects: 132
Study 21859656 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy drink (240 cc)
Number of subjects: 23
Study 21859656 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 23
Study 19706088 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil cream applied once or twice daily under occlusion for 6 weeks
Number of subjects: 39
Study 18257271 — intervention group
Group type: EXPERIMENTAL
Intervention: Migu tablet (MG)
Number of subjects: 192
Study 18257271 — intervention group
Group type: EXPERIMENTAL
Intervention: XLGB group
Number of subjects: 192
Study 18257271 — intervention group
Group type: COMPARATOR
Intervention: Leli group
Number of subjects: 192
Study 18257271 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 192
Study 15218812 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b 8 MIU given subcutaneously every other day for two years
Number of subjects: 73
Study 15218812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 11451784 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure intervention (patients visited 2-3 times to disclose emotionally important events)
Number of subjects: 161
Study 11451784 — intervention group
Group type: COMPARATOR
Intervention: Control (normal care from general practitioners)
Number of subjects: 161
Study 11451784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (disclosure patients)
Number of subjects: 161
Study 9487328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG)
Number of subjects: 162
Study 8110549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure group
Number of subjects: 40
Study 8110549 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 2470310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, 80 mg/m2 alone (CDDP regimen)
Number of subjects: 241
Study 2470310 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (MOB-P: vincristine 1 mg, methotrexate 10 mg/m2 d 1, 2, 3, bleomycin 10 mg/m2 d 1, 2, 3)
Number of subjects: 241
Study 2470310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin alone (CDDP regimen)
Number of subjects: 241
Study 2470310 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (MOB-P)
Number of subjects: 241
Study 2470310 — intervention group
Group type: EXPERIMENTAL
Intervention: Among responders
Number of subjects: 241
Study 31605797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed + Gefitinib (P+G)
Number of subjects: 191
Study 31605797 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 191
Study 29844250 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids (Fs)
Number of subjects: 98
Study 29844250 — intervention group
Group type: EXPERIMENTAL
Intervention: Centella asiatica (Ca)
Number of subjects: 98
Study 29844250 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (Control Group C)
Number of subjects: 98
Study 28802634 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration in RS group
Number of subjects: 24
Study 28802634 — intervention group
Group type: COMPARATOR
Intervention: Heparin administration in NS group
Number of subjects: 24
Study 26263381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 39
Study 24062371 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDS‐ES (PEDS Early Screener)
Number of subjects: 87
Study 24062371 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDS‐ES without additional risk factors
Number of subjects: 87
Study 20403476 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Number of subjects: 1190
Study 18559232 — intervention group
Group type: EXPERIMENTAL
Intervention: Red peony root decoction
Number of subjects: 96
Study 18559232 — intervention group
Group type: COMPARATOR
Intervention: Rhubarb
Number of subjects: 96
Study 16951825 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion (WR)
Number of subjects: 154
Study 16951825 — intervention group
Group type: COMPARATOR
Intervention: No Reperfusion (WtR)
Number of subjects: 154
Study 12716399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-health advocate home visiting program
Number of subjects: 0
Study 11126939 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming
Number of subjects: 0
Study 11126939 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic categorization
Number of subjects: 0
Study 9349079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous ephedrine 0.25 mg.kg‐1
Number of subjects: 46
Study 9349079 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluid preloading with Hartmann's solution 20 ml.kg‐1
Number of subjects: 46
Study 8223792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (50 micrograms bd)
Number of subjects: 258
Study 8223792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (current therapy)
Number of subjects: 258
Study 3707815 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir tablets (2 X 200 mg)
Number of subjects: 9
Study 3707815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of acyclovir (400 mg in 500 ml of 5% dextrose solution over 4 h)
Number of subjects: 9
Study 3707815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipping acyclovir solution (same as infusion, sipped at 10.4 ml every 5 min for 4 h)
Number of subjects: 9
Study 3707815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of acyclovir (400 mg)
Number of subjects: 9
Study 3707815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipping acyclovir solution
Number of subjects: 9
Study 29762363 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP-T vaccine (group 1)
Number of subjects: 529
Study 29762363 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted DTaP-HB-IPV/PRP-T comparator (group 2)
Number of subjects: 529
Study 26980210 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma betaine
Number of subjects: 3621
Study 26980210 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine betaine
Number of subjects: 3621
Study 26980210 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylglycine
Number of subjects: 3621
Study 26980210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine
Number of subjects: 3621
Study 26980210 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sarcosine
Number of subjects: 3621
Study 23868810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg
Number of subjects: 296
Study 23868810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 22770758 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 60
Study 22770758 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia without HTEA (Control)
Number of subjects: 60
Study 20798075 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 20798075 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 17662090 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Citrulline (3 g bid)
Number of subjects: 20
Study 17662090 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Number of subjects: 20
Study 16380708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg daily for 6 months)
Number of subjects: 60
Study 16380708 — intervention group
Group type: COMPARATOR
Intervention: Low caloric diet
Number of subjects: 60
Study 12747281 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 500 mg
Number of subjects: 42
Study 12747281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10758047 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 659
Study 10758047 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 659
Study 8821514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine extended release capsule (Aprical retard)
Number of subjects: 24
Study 8821514 — intervention group
Group type: COMPARATOR
Intervention: Standard retard tablet
Number of subjects: 24
Study 1483293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (75 g) + pyridostigmine (120 mg)
Number of subjects: 8
Study 1483293 — intervention group
Group type: COMPARATOR
Intervention: Placebo + pyridostigmine (120 mg)
Number of subjects: 8
Study 1483293 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose (75 g)
Number of subjects: 8
Study 1483293 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine (120 mg) alone
Number of subjects: 8
Study 2990708 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (cyclophosphamide, vincristine, semustine)
Number of subjects: 28
Study 2990708 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (cyclophosphamide, vincristine, semustine)
Number of subjects: 28
Study 2990708 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (cyclophosphamide, vincristine, semustine) in patients with extensive disease
Number of subjects: 28
Study 2990708 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (cyclophosphamide, vincristine, semustine) in patients with extensive disease
Number of subjects: 28
Study 29945245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Tension Technique (NTT)
Number of subjects: 54
Study 29945245 — intervention group
Group type: COMPARATOR
Intervention: Sham technique
Number of subjects: 54
Study 29782217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 1902
Study 29782217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 1902
Study 29782217 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 1902
Study 29782217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks in patients with eosinophil count ≥300/mm³
Number of subjects: 1902
Study 29782217 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo in patients with eosinophil count ≥300/mm³
Number of subjects: 1902
Study 29782217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 1902
Study 26556577 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 41
Study 26556577 — intervention group
Group type: EXPERIMENTAL
Intervention: βTCP/HA
Number of subjects: 41
Study 26556577 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + βTCP/HA
Number of subjects: 41
Study 26556577 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 41
Study 24878827 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (90 minutes/day for 15 days)
Number of subjects: 68
Study 24878827 — intervention group
Group type: COMPARATOR
Intervention: Walking (90 minutes/day for 15 days)
Number of subjects: 68
Study 22412837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day for 14 days)
Number of subjects: 39
Study 22412837 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (40 mg/day for 4 days)
Number of subjects: 39
Study 20113919 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes (17.69 hours/week)
Number of subjects: 434
Study 20113919 — intervention group
Group type: COMPARATOR
Intervention: Controls (4.69 hours/week)
Number of subjects: 434
Study 18018838 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation
Number of subjects: 129
Study 18018838 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation
Number of subjects: 129
Study 18018838 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II <= 20
Number of subjects: 129
Study 18018838 — intervention group
Group type: COMPARATOR
Intervention: APACHE II > 20
Number of subjects: 129
Study 16153510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LV restrictive pattern (n=56)
Number of subjects: 126
Study 16153510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pseudonormalization pattern (n=36)
Number of subjects: 126
Study 16153510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with abnormal relaxation pattern (n=34)
Number of subjects: 126
Study 16153510 — intervention group
Group type: COMPARATOR
Intervention: Patients with ejection fraction of 35% or less (pseudonormal group)
Number of subjects: 126
Study 16153510 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with ejection fraction of 35% or more)
Number of subjects: 126
Study 16153510 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of patients with decreased LV systolic function to age-matched control subjects
Number of subjects: 126
Study 12647845 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of insulin lispro before the afternoon meal
Number of subjects: 43
Study 12647845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 43
Study 9709768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative corneal cauterization (group A)
Number of subjects: 29
Study 9709768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cauterization, group B)
Number of subjects: 29
Study 7972810 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated endorectal PPA coils
Number of subjects: 71
Study 7972810 — intervention group
Group type: COMPARATOR
Intervention: Pelvic phased-array (PPA) coils
Number of subjects: 71
Study 7972810 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus image interpretation
Number of subjects: 71
Study 7972810 — intervention group
Group type: COMPARATOR
Intervention: Single-reader image interpretation
Number of subjects: 71
Study 2438799 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (1600 anti-Xa units b.d.)
Number of subjects: 60
Study 2438799 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (2400 anti-Xa units b.d.)
Number of subjects: 60
Study 2438799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2438799 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (800 anti-Xa units b.d.)
Number of subjects: 60
Study 31937653 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS-TAU
Number of subjects: 214
Study 31937653 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 214
Study 30170456 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump technique
Number of subjects: 94
Study 30170456 — intervention group
Group type: COMPARATOR
Intervention: On-pump technique
Number of subjects: 94
Study 26547499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (once-daily dosage)
Number of subjects: 308
Study 26547499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with ribavirin
Number of subjects: 308
Study 26547499 — intervention group
Group type: COMPARATOR
Intervention: Ledipasvir/Sofosbuvir
Number of subjects: 308
Study 24556911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L‐alanyl‐L‐glutamine dipeptide supplementation (0.5 g/kg body weight/day) for 5 days
Number of subjects: 142
Study 24556911 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 142
Study 24556911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glutamine levels at day 6
Number of subjects: 142
Study 23735512 — intervention group
Group type: EXPERIMENTAL
Intervention: Subendocardial viability ratio (SEVR) in living patients
Number of subjects: 212